In this video, Scarlett Gomez, MD, PhD, discusses the background and findings of the study, “Active surveillance for watchful waiting in clinically low-risk prostate cancer patients in the SEER database with and without an Oncotype DX genomic prostate score assay,” presented at the 2021 American Urological Association Annual Meeting. Gomez is a professor in the department of epidemiology and biostatistics at the University of California, San Francisco.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.